Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008, Updated: 06/01/2009) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.
Celecoxib Reduces Risk of Precancerous Colorectal Polyps: Five-Year Results of APC Trial
(Posted: 04/23/2008, Updated: 05/21/2009) - The five-year results of the Adenoma Prevention with Celecoxib (APC) trial indicate that two years after daily use of celecoxib (Celebrex®) has ended, there continues to be a modest reduction in the recurrence of colorectal polyps, according to a presentation at the 2008 American Association for Cancer Research annual meeting.
Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
(Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.